Cost Effectiveness of Dose Optimized Ustekinumab Versus Switching to Anti-Tnfs Following Partial Response to Ustekinumab Every Twelve Weeks in Patients with Moderate to Severe Plaque Psoriasis
Abstract
Authors
Y Poulin U Lathia EA Griffin K Perampaladas